Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease

Hepatology - Tập 47 Số 4 - Trang 1363-1370
W. Ray Kim1,2, Steven L. Flamm3, Adrian M. Di Bisceglie4, Henry C. Bodenheimer5
1Mayo Clinic College of Medicine, Rochester, MN;
2fax : 507-538-3974
3Feinberg School of Medicine, Northwestern University, Chicago, IL
4Saint Louis University School of Medicine, St. Louis, MO
5Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Price, 1979, Liver and biliary diseases-pathophysiology, diagnosis, management, 381

Ishiguro, 1991, Complete amino acid sequence of human liver cytosolic alanine aminotransferase (GPT) determined by a combination of conventional and mass spectral methods, Biochemistry, 30, 10451, 10.1021/bi00107a013

Sohocki, 1997, Human glutamate pyruvate transaminase (GPT): localization to 8q24.3, cDNA and genomic sequences, and polymorphic sites, Genomics, 40, 247, 10.1006/geno.1996.4604

Fraser, 1991, Biological variation in clinical chemistry: an update: collated data, 1988-1991, Arch Pathol Lab Med, 116, 916

Cordoba, 1999, Diurnal variation of serum alanine transaminase activity in chronic liver disease, HEPATOLOGY, 28, 1724, 10.1002/hep.510280640

Williams, 1988, Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis, Gastroenterology, 95, 734, 10.1016/S0016-5085(88)80022-2

Sheth, 1998, AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection, Am J Gastroenterol, 93, 44, 10.1111/j.1572-0241.1998.044_c.x

Prati, 2002, Updated definitions of healthy ranges for serum alanine aminotransferase levels, Ann Intern Med, 137, 1, 10.7326/0003-4819-137-1-200207020-00006

Siest, 1975, Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations and reference values, Clin Chem, 21, 1077, 10.1093/clinchem/21.8.1077

Salvaggio, 1991, Body mass index and liver enzyme activity in serum, Clin Chem, 37, 720, 10.1093/clinchem/37.5.720

Piton, 1998, Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C, HEPATOLOGY, 27, 1213, 10.1002/hep.510270505

Nuttall, 1968, Creatinine kinase and glutamic oxoloacetic transaminase activity in serum: kinetics of change with exercise and effect of physical conditioning, J Lab Clin Med, 51, 257

Dufour, 1998, Effects of habitual exercise on routine laboratory tests, Clin Chem, 44, 136

Kundrotas, 1993, Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors, Dig Dis Sci, 39, 2145, 10.1007/BF01299887

Mathiesen, 1999, The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients, Scand J Gastroenterol, 34, 85, 10.1080/00365529950172880

Ludwig, 1980, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clinic Proc, 55, 434

Ruhl, 2003, Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States, Gastroenterology, 124, 71, 10.1053/gast.2003.50004

Bacon, 1994, Non-alcoholic steatohepatitis: an expanded clinical entity, Gastroenterology, 107, 1103, 10.1016/0016-5085(94)90235-6

Hedley, 2004, Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.[see comment], JAMA, 291, 2847, 10.1001/jama.291.23.2847

Bray, 2006, Epidemiology, trends, and morbidities of obesity and the metabolic syndrome, Endocrine, 29, 109, 10.1385/ENDO:29:1:109

Kerner, 2005, Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome, Arterioscler Thromb Vasc Biol, 25, 193, 10.1161/01.ATV.0000148324.63685.6a

Kunde, 2005, Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women, HEPATOLOGY, 42, 650, 10.1002/hep.20818

Reid, 2001, Nonalcoholic steatohepatitis, Gastroenterology, 121, 710, 10.1053/gast.2001.27126

Kim, 2001, Outcome of hospital care of liver disease associated with hepatitis C in the United States, HEPATOLOGY, 33, 201, 10.1053/jhep.2001.20798

Sorbi, 1999, The ratio of aspartate aminotransferease to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease, Am J Gastroenterol, 94, 1018, 10.1111/j.1572-0241.1999.01006.x

Diehl, 1984, Relationship between pyridoxal 5′-phosphate deficiency and aminotransferase levels in alcoholic hepatitis, Gastroenterology, 86, 632, 10.1016/S0016-5085(84)80110-9

Ewing, 1984, Detecting alcoholism: the CAGE questionnaire, JAMA, 252, 1905, 10.1001/jama.1984.03350140051025

Selzer, 1971, The Michigan alcoholism screening test: the quest for a new diagnostic instrument, Am J Psychiatry, 127, 1653, 10.1176/ajp.127.12.1653

Pinto, 1996, Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients, Dig Dis Sci, 41, 172, 10.1007/BF02208601

Armstrong GL Wasley A Simard EP McQuillan GM Kuhnert WL Alter MJ The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Alter, 1999, The prevalence of hepatitis C virus infection in the United States, 1988 through 1994, N Engl J Med, 341, 556, 10.1056/NEJM199908193410802

Inglesby, 1999, A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use, HEPATOLOGY, 29, 590, 10.1002/hep.510290219

Conry-Cantilena, 1996, Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection, N Engl J Med, 334, 1691, 10.1056/NEJM199606273342602

Okanoue, 2005, A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase, J Hepatol, 43, 599, 10.1016/j.jhep.2005.04.008

Puoti, 1997, Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels, HEPATOLOGY, 26, 1393, 10.1002/hep.510260603

Nutt, 2000, Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels, Am J Med, 109, 62, 10.1016/S0002-9343(00)00381-8

Kyrlagkitsis, 2003, Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT, Am J Gastroenterol, 98, 1588, 10.1111/j.1572-0241.2003.07539.x

Margolis, 1995, Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations, JAMA, 274, 1201, 10.1001/jama.1995.03530150025029

Lok, 2001, Chronic hepatitis B, HEPATOLOGY, 34, 1225, 10.1053/jhep.2001.29401

Yuen, 2005, Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications, Gut, 54, 1610, 10.1136/gut.2005.065136

Yuen, 2003, A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy, Gut, 52, 416, 10.1136/gut.52.3.416

Green, 2002, AGA technical review on the evaluation of liver chemistry tests, Gastroenterology, 123, 1367, 10.1053/gast.2002.36061

Krawitt, 1996, Autoimmune hepatitis, N Engl J Med, 334, 897, 10.1056/NEJM199604043341406

Lohse, 1999, Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitis form of PBC genetically susceptible individuals, HEPATOLOGY, 29, 1078, 10.1002/hep.510290409

Ponsioen, 1998, Primary sclerosing cholangitis: a clinical review, Am J Gastroenterol, 93, 515, 10.1111/j.1572-0241.1998.157_b.x

Adams, 1991, Clinical presentation of hemochromatosis: a changing scene, Am J Med, 90, 445, 10.1016/0002-9343(91)90604-V

Summers, 1990, Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index, HEPATOLOGY, 12, 20, 10.1002/hep.1840120105

Crystal, 1990, ALpha-1 antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy, J Clin Invest, 85, 1343, 10.1172/JCI114578

Bardella, 1999, Chronic unexplained hypertransaminasemia may be caused by occult celiac disease, HEPATOLOGY, 29, 654, 10.1002/hep.510290318

Kim, 2004, Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study, BMJ, 328, 983, 10.1136/bmj.38050.593634.63

Kim, 2008, Serum aminotransferase activity and risk of mortality in a U. S. community population, HEPATOLOGY, 47

Ioannou, 2006, Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States, HEPATOLOGY, 43, 1145, 10.1002/hep.21171

Hanley, 2005, Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study, Diabetes, 54, 3140, 10.2337/diabetes.54.11.3140

1957, Commission on chronic illness: prevention of chronic illness (vol I). Chronic illness in the United States, 45

Wilson, 1968, Principles and practice of screening for disease

Kim, 2002, Burden of liver disease in the United States: summary of a workshop, HEPATOLOGY, 36, 227, 10.1053/jhep.2002.34734

Zaman, 1985, Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients, Lancet, 1, 1357, 10.1016/S0140-6736(85)91785-4

Parkin, 2001, Estimating the world cancer burden: Globocan 2000, Int J Cancer, 94, 153, 10.1002/ijc.1440

El-Serag, 2003, The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update, Annals of Internal Medicine, 139, 817, 10.7326/0003-4819-139-10-200311180-00009

El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056/NEJM199903113401001

Kim, 2005, Mortality and hospital utilization for hepatocellular carcinoma in the United States, Gastroenterology, 129, 486, 10.1016/j.gastro.2005.05.001

Poynard, 1997, Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups, Lancet, 349, 825, 10.1016/S0140-6736(96)07642-8